Dear John,

Ottawa’s changes to the Patented Medicines Regulations are intended to reduce drug prices.

But a new study published by the Fraser Institute today finds that these changes will also likely result in delayed – or worse, limited – access to new life-saving medicines.

The potential lower prices will discourage pharmaceutical companies from launching new products in Canada, and reduce the financial incentives to develop and manufacture new medicines, treatments, and cures in Canada.

Worth noting is that COVID-19 vaccines were effectively exempt from regular pricing oversight, suggesting that the federal government is aware of the discouraging effect such restrictions have on innovation in the pharmaceutical industry.

Check out the full study here, and please share this important information on social media!

Sincerely,

Niels Veldhuis
President
The Fraser Institute